Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
tRNA methyltransferase 1-like protein (TRMT1L) is an RNA-modifying enzyme that specifically dimethylates a guanine residue at position 27 of tyrosine tRNA (tRNA^Tyr) using S-adenosyl-L-methionine as the methyl group donor[1][2][4]. This modification, N2,N2-dimethylguanosine (m^2,2G), is critical for the stability and translational function of tRNA, particularly for tyrosine and serine codons[1]. TRMT1L is also required for maintaining another modification, acp3U, in the D-loop of several cytoplasmic tRNAs. Loss of TRMT1L activity results in reduced levels of certain tRNAs and is linked to impaired neuronal function and developmental disorders in humans; mouse models show that the gene is involved in motor coordination and postnatal brain function[1][2]. The enzyme operates in parallel with its paralog, TRMT1, which modifies a nearby guanine at position 26 of tRNA^Tyr[1]. No direct drug interactions or biomarker roles are currently described for TRMT1L.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA methyltransferase 1-like protein (TRMT1L).